Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics (NASDAQ: CRSP), ... Its price in the U.S. is $2.2 million. Its total addressable market includes about 35,000 patients in the U.S. and Europe and an additional 23,000 in Saudi ...
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
Image source: CRISPR Therapeutics. 2. Profitability remains elusive. There's some optimism that CRISPR Therapeutics is still in the early stages of a significant long-term opportunity.
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and open up specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within living organisms.
In June 2021, Intellia made history by announcing interim Phase 1 data for NTLA-2001, demonstrating the ability to precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. This was the first time any human clinical data has been published for an in vivo gene editing therapeutic candidate.
CRISPR Therapeutics AG (CRSP) closed at $76.50 in the latest trading session, marking a +0.9% move from the prior day.